Search
toripalimab-tpzi (Loqtorzi)
Indications:
- for use in combination with cisplatin & gemcitabine for 1st-line treatment of adults with metastatic or recurrent, locally advanced nasopharyngeal carcinoma
- for use as a single agent for adults with recurrent unresectable or metastatic nasopharyngeal carcinoma with disease progression on or after platinum-containing chemotherapy
Contraindications:
- advise against breastfeeding
Dosage:
- in combination with cisplatin & gemcitabine:
- 240 mg intravenously every 3 weeks
- as a single agent
- 3 mg/kg intravenously every 2 weeks
- 1st infusion: infuse over 60 minutes
- subsequent infusions: infuse over 30 minutes if no infusion-related reaction with 1st infusion
240 mg/6 mL (40 mg/mL) solution in a single-dose vial
Adverse effects:
- immune-mediated reactions may be severe of fatal may occur in any organ > 20%
- nausea, vomiting, anorexia, constipation, diarrhea
- hypothyroidism, peripheral neuropathy, musculoskeletal pain
- rash, pyrexia, cough, dizziness, insomnia, malaise
- upper respiratory tract infection
Mechanism of action:
- humanized IgG4 monoclonal antibody that binds to the PD-1 receptor, blocks its interaction with PD-L1 & PD-L2, releasing PD-1 pathway-mediated inhibition of the immune response, including the anti-tumor immune response.
Interactions
drug adverse effects of pharmaceutical monoclonal antibodies
General
antineoplastic monoclonal antibody
References
- U.S. Food and Drug Administration (FDA)
FDA approves toripalimab-tpzi for nasopharyngeal carcinoma.
https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-toripalimab-tpzi-nasopharyngeal-carcinoma
- HIGHLIGHTS OF PRESCRIBING INFORMATION
Loqtorzi (toripalimab-tpzi) injection, for intravenous use
https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/761240s000lbl.pdf